Yahoo
Toronto - Delayed Quote CAD

Cannara Biotech Inc. (LOVE.TO)

2.0100 +0.0700 (+3.61%)
At close: October 30 at 2:35:36 PM EDT
Chart Range Bar
Loading chart for LOVE.TO
  • Previous Close 1.9400
  • Open 1.9600
  • Bid 2.0000 x --
  • Ask 2.0200 x --
  • Day's Range 1.9600 - 2.0200
  • 52 Week Range 1.5500 - 2.3700
  • Volume 43,038
  • Avg. Volume 43,241
  • Market Cap (intraday) 198.552M
  • Beta (5Y Monthly) 0.27
  • PE Ratio (TTM) 18.27
  • EPS (TTM) 0.1100
  • Earnings Date Nov 23, 2026
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 3.38

Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivative products in Canada. The company operates in two segment Cannabis operations and Real estate operations. It offers its products under TRIBAL, nugz, and ORCHID CBD brand name. The company sells its products through wholesalers and online merchandisers. In addition, it engages in the real estate operations. Cannara Biotech Inc. was incorporated in 2017 and is headquartered in Saint-Laurent, Canada.

cannara.ca

452

Full Time Employees

August 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .

YTD Return

LOVE.TO
17.54%
S&P/TSX Composite index (^GSPTSE)
11.78%

1-Year Return

LOVE.TO
21.08%
S&P/TSX Composite index (^GSPTSE)
18.03%

3-Year Return

LOVE.TO
107.22%
S&P/TSX Composite index (^GSPTSE)
88.90%

5-Year Return

LOVE.TO
1,446.15%
S&P/TSX Composite index (^GSPTSE)
69.32%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 31.83M
Earnings 4.84M
Profit Margin 15.22%

Q2

FY26

Q3

FY26

0
10M
20M
30M
8.0%
10.0%
12.0%
14.0%

Analyst Insights

View More

Analyst Price Targets

3.00
3.38 Average
2.0100 Current
4.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    9.25%

  • Return on Assets (ttm)

    6.26%

  • Return on Equity (ttm)

    9.68%

  • Revenue (ttm)

    117.33M

  • Net Income Avi to Common (ttm)

    10.86M

  • Diluted EPS (ttm)

    0.1100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    21.81M

  • Total Debt/Equity (mrq)

    29.40%

  • Levered Free Cash Flow (ttm)

    3.19M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: